“Targeting OX40 With GBR 830, An OX40 Antagonist, Inhibits T Cell-Mediated Pathological Responses”. 2018. SKIN The Journal of Cutaneous Medicine 2 (December): S62. https://doi.org/10.25251/skin.2.62.